adaptatiVe Endovascular Strategy to the CloT MRI in Large Intracranial Vessel Occlusion (VECTOR)
In the VECTOR trial, the aim is to analyze, in case of SVS+ occlusions, a first line Embotrap II added to CA combined strategy compare to CA alone strategy.
Many practitioners are convinced that a first line strategy with CA alone is easy, safe, rapid and efficient. Maybe, after two, three, four ... passes and with the secondary help of a combined strategy, a high rate of eTICI 2b/3 could be reached with a CA first line strategy. But this could go with a higher number of passes, a waste of time and a suboptimal angiographic results (eTICI 2b) due to distal emboli, especially in case of friable, non-well organized, red blood cell rich (RBC) i.e. SVS + thrombi (25-28). This could, be related to worst clinical outcome at 3 months. VECTOR asks a relevant question: Do the invetigators have to add the use of an Embotrap II or III to the CA, from the first passes, in case of SVS+ clots?
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Sudden occlusion of an intracranial artery by a thrombus represents the initial and pivotal event of large vessel occlusion acute ischemic stroke (AIS). The primary goal of AIS treatment is to re-open this artery with intravenous tissue-type plasminogen activator infusion (IV t-PA) and/or endovascular therapy (EVT). Thrombus characterization could be useful to predict AIS etiology, IV t-PA response and to adapt the device or technique for EVT. Especially, approaching the red blood cell (RBC) content of the thrombus would be helpful to plan a treatment strategy or identify specific EVT approaches in order to maximize the rate of early successful reperfusion .
The susceptibility vessel sign (SVS) on T2*-MRI sequence is defined as a hypo-intense signal exceeding the diameter of the contralateral artery located at the site of the thrombus. Several studies have demonstrated SVS to be a negative predictor of early reperfusion after IV t-PA and an incentive to EVT . Two studies identified a correlation between the SVS and the thrombus composition (specifically the RBC composition). In the ASTER trial, the presence of SVS impacted the success rate of the EVT strategy. In the SVS (+) sub-population of this study, compared to contact aspiration (CA), patients treated with stent retrievers achieved higher rates of complete reperfusion within fewer passes, which translated into a better functional outcome. In the absence of SVS, no differences were observed between the two techniques. Furthermore; based on the ASTER and THRACE trial populations treated with stent retriever as a first line strategy, a higher rate of favorable clinical outcome at 3 months in SVS (+) patients was recently found . Hence, that differences in terms of reperfusion results are thought to be related to different clot compositions between SVS + and SVS - occlusions.
In the VECTOR trial, the aim is to analyze, in case of SVS+ occlusions, a first line Embotrap II added to CA combined strategy compare to CA alone strategy.
Many practitioners are convinced that a first line strategy with CA alone is easy, safe, rapid and efficient. Maybe, after two, three, four passes and with the secondary help of a combined strategy, a high rate of eTICI 2b/3 could be reached with a CA first line strategy. But this could go with a higher number of passes, a waste of time and a suboptimal angiographic results (eTICI 2b) due to distal emboli, especially in case of friable, non-well organized, red blood cell rich (RBC) i.e. SVS + thrombi. This could, be related to worst clinical outcome at 3 months.
VECTOR asks a relevant question: Do the investigators have to add the use of an Embotrap II or III to the CA, from the first passes, in case of SVS+ clots? The hypothesis in the VECTOR trial is that the Embotrap II or III, thanks to its dedicated design will help to the stabilization of friable clots and allow better retrieving of SVS + thrombi in a lower number of passes.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
-
Amiens, Frankreich
- CHU amiens-Picardie
-
Angers, Frankreich
- CH Angers
-
Bayonne, Frankreich, 64109
- CH Côte Basque
-
Bordeaux, Frankreich
- Hôpital Pellegrin - CHU Bordeaux
-
Brest, Frankreich
- CHRU Brest
-
Le Kremlin-Bicêtre, Frankreich
- Hopital Bicetre
-
Lille, Frankreich
- Hôpital Roger Salengro - CHR Lille
-
Limoges, Frankreich
- CHU Limoges
-
Lyon, Frankreich
- Hospices civils Lyon
-
Marseille, Frankreich, 13385
- CHU Marseille - Hôpital la Timone
-
Montpellier, Frankreich
- CHU Gui de Chauliac
-
Nancy, Frankreich
- CHU Nancy
-
Nantes, Frankreich
- CHU de Nantes
-
Paris, Frankreich, 75019
- Fondation Ophtalmologique Adolphe de Rothschild
-
Paris, Frankreich
- La Pitié Salpêtrière
-
Paris, Frankreich
- Hôpital Ste Anne
-
Pau, Frankreich, 64000
- CH Pau
-
Reims, Frankreich
- Hôpital Maison Blanche - CHU Reims
-
Rennes, Frankreich
- Hopital Pontchaillou - CHU Rennes
-
Strasbourg, Frankreich, 67000
- CHU Strasbourg
-
Suresnes, Frankreich
- Hôpital Foch
-
Tours, Frankreich
- Hôpital Bretonneau - CHU Tours
-
Vannes, Frankreich
- CH Bretagne Atlantique
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Age 18 and older (i.e., candidates must have had their 18th birthday)
- Puncture carried out within 24 hours of first symptoms
- Suitable 1.5T MRI T2 * Gradient echo that shows a clear susceptibility vessel sign facing the occlusion
- Neuroimaging demonstrates large vessel proximal occlusion (distal ICA through MCA bifurcation, M1 or proximal M2)
- Patient or trustworthy person informed about the study and having orally consented to participation in the study. If the patient is unable to receive information and no trustworthy person can be contacted during screening for the study, trial inclusion will be completed as an emergency procedure by the investigator, in compliance with the French laws
- With or without intravenous thrombolysis
Exclusion Criteria:
- Absence of large vessel occlusion on non-invasive imaging
- Known or suspected pre-existing (chronic) large vessel occlusion in the symptomatic territory
- Suspected pregnancy; if, in a woman is of child-bearing potential, a urine or serum beta HCG test is positive
- Severe contrast medium allergy or absolute contraindication to use of iodinated products
- Clinical history, past imaging or clinical judgment suggests that the intracranial occlusion is chronic
- Patient has severe or fatal comorbidities that will likely prevent improvement or follow-up or that will render the procedure unlikely to benefit the patient
- Acute ischemic stroke involving posterior circulation (vertebro-basilar occlusion)
- Angiographic evidence of carotid dissection or tandem cervical occlusion or stenosis requiring treatment
- Pregnant or breast-feeding women
- Patient benefiting from a legal protection
- Non-membership of a national insurance scheme
- Opposition of the patient or (in case of inclusion as a matter of urgency) of the trustworthy person
- Patient with modified Rankin score > 3 before qualifying stroke
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: combined EMBOTRAP II or III and Contact Aspiration
|
refer to title
|
|
Aktiver Komparator: Contact Aspiration alone
|
refer to title
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
The rate of near to complete reperfusion after 3 passes of the device defined by a modified treatment in cerebral infarction (eTICI) score of 2c/3
Zeitfenster: At Day 0 immediately after 3 passes
|
Preliminary data suggested in case of SVS+ occlusions a superiority of the first line SR strategy in terms of eTICI2c/3 after 3 passes compared to first line CA alone.The first pass (FPE) is an ambitious technical endpoint defined as a successful reperfusion obtained after the first pass that has been recently associated with an increased probability of favorable clinical outcome, a reduced mortality rate and procedural adverse events.However, this constitutes a "very technical" endpoint and the external validity in daily practice would be reduced compared to the three passes cut-off.Even if a FPE eTICI 2b, 2c or 3 has shown better clinical outcome compared to a final eTICI 2b, 2c or 3,there is no study that has proved the better clinical outcome when compared FPE eTICI 2b,2c or 3 to three passes eTICI 2b,2c or 3.Last, there was no preliminary data that suggests in case of SVS+ occlusions, a superiority of the first pass SR strategy in terms eTICI2c/3 compared to first pass CA alone.
|
At Day 0 immediately after 3 passes
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Near to complete first-pass effect
Zeitfenster: Day 0 immediately after first pass
|
Defined as a eTICI 2c/3 after first pass device
|
Day 0 immediately after first pass
|
|
Complete first-pass effect
Zeitfenster: Day 0 immediately after first pass
|
Defined as a eTICI 3 after first pass device
|
Day 0 immediately after first pass
|
|
Complete reperfusion
Zeitfenster: Day 0 immediately after three passes
|
Defined as eTICI 3 after three passes
|
Day 0 immediately after three passes
|
|
Final near to complete reperfusion
Zeitfenster: Day 0 at the end of the intervention
|
Defined as eTICI 2c/3 final
|
Day 0 at the end of the intervention
|
|
Final complete reperfusion
Zeitfenster: Day 0 at the end of the intervention
|
Defined as eTICI 3
|
Day 0 at the end of the intervention
|
|
Time to achieve eTICI 2c or better revascularization
Zeitfenster: Day 0
|
Time to achieve eTICI 2c or better revascularization
|
Day 0
|
|
Time between groin puncture to clot contact
Zeitfenster: Day 0
|
Time between groin puncture to clot contact
|
Day 0
|
|
Rate of functional independence
Zeitfenster: At 90days
|
Defined as a modified Rankin scale (mRS) 0-2
|
At 90days
|
|
Rate of excellent functional outcome
Zeitfenster: At 90days
|
Defined as a mRS 0-1
|
At 90days
|
|
The distribution of mRs scores
Zeitfenster: At 90days
|
Combining scores of 9 and 10
|
At 90days
|
|
Change in NIHSS from baseline to 24 hours
Zeitfenster: Baseline and 24hours
|
Change in NIHSS
|
Baseline and 24hours
|
|
Rate of symptomatic and asymptomatic intracerebral hemorrhage
Zeitfenster: At 24hrs
|
Assessment of symptomatic and asymptomatic intracerebral hemorrhage at MRI or CT scan 24h after thrombectomy
|
At 24hrs
|
|
Rate of parenchymal hematoma type 1 and 2
Zeitfenster: At 24hrs
|
Assessment of parenchymal hematoma type 1 and 2
|
At 24hrs
|
|
Rate of all-cause mortality at 90 days
Zeitfenster: At 90days
|
Assessment of all-cause mortality at 90 days
|
At 90days
|
|
Rate of periprocedural complications
Zeitfenster: At 90days
|
Occurrence of emboli to new territory, vasospasm, dissection, perforation and subarachnoid hemorrhage
|
At 90days
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Romain Bourcier, CHU Nantes
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- RC19_0174
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .